Imuldosa (Ustekinumab)

Ustekinumab is a monoclonal antibody that binds to the p40 subunit shared by interleukin‑12 and interleukin‑23. This binding blocks the cytokines from activating their receptors, thereby reducing Th1 and Th17 driven inflammation that underlies psoriasis, psoriatic arthritis, and Crohn's disease.

The dose and infusion schedule of Imuldosa are individualized by the prescribing healthcare professional based on the patient’s weight, disease severity, prior treatment response, and clinical guidelines. Patients should follow the prescriber’s specific instructions.

Safety data for ustekinumab in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Imuldosa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Imuldosa (ustekinumab) targets both IL‑12 and IL‑23, whereas some alternatives focus on a single cytokine (e.g., IL‑17 inhibitors). This dual inhibition can offer efficacy in patients who have not responded to agents that block only one pathway, but the choice of therapy depends on individual disease characteristics, prior treatment history, and safety considerations.

Imuldosa should be stored in a refrigerator at 2 °C to 8 °C. It must be kept in its original packaging, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it should be used promptly according to the manufacturer’s guidance.

Imuldosa is supplied as a sterile intravenous solution. It is administered by a qualified healthcare professional through an IV infusion, typically over a period of 30 to 60 minutes, following the dosing schedule prescribed by the treating physician.

The most serious risks include severe or opportunistic infections (such as tuberculosis), potential development of malignancies, hypersensitivity reactions including anaphylaxis, and rare cardiovascular events. Patients should be monitored closely for signs of infection, new skin lesions, or allergic reactions throughout treatment.

Imuldosa is contraindicated in patients with known hypersensitivity to ustekinumab or any component of the formulation. It should also be avoided in individuals with active serious infections, uncontrolled tuberculosis, or those who have received live vaccines within four weeks of dosing.